Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. 2002

Shigehira Saji, and Yoko Omoto, and Chikako Shimizu, and Margaret Warner, and Yukiko Hayashi, and Shin-ichiro Horiguchi, and Toru Watanabe, and Shin-ichi Hayashi, and Jan-Ake Gustafsson, and Masakazu Toi
Department of Surgery, Breast Oncology Unit, Tokyo Metropolitan Komagome Hospital, 113-8677 Tokyo, Japan. ss-saji@wa2.so-net.ne.jp

Estrogen receptor (ER) (beta)cx, a splice variant of ERbeta, is a dominant repressor of ER(alpha) function. In this study we investigated the possibility that because the progesterone receptor (PR) gene is a downstream target of activated ER(alpha), in ER(alpha)-positive breast cancers, expression of ER(beta)cx would result in repression of PR. In ER(alpha)-positive MCF-7 cells, stable transfection of an ER(beta)cx expression vector resulted in reduced expression of PR without affecting ER(alpha) expression. In breast cancers, immunohistochemical evaluation of ER(alpha)-positive foci for the expression of PR and ER(beta)cx revealed a significant correlation between a PR-negative phenotype and the presence of ER(beta)cx within the foci. However, when entire lesions were evaluated by Allred scoring in 115 ER(alpha)-positive breast cancer specimens, the presence of two distinct groups of patients could be discerned. One group expressed ER(beta)cx and had very reduced levels of PR expression, as expected. The second group showed both ER(beta)cx and high levels of PR. To evaluate the role of ER(beta)cx in sensitivity to tamoxifen, 18 core needle biopsies, obtained before preoperative treatment with tamoxifen, were investigated. The results show that expression of ER(beta)cx in primary lesions correlated with a poor response to tamoxifen, especially in cancers with a low PR expression in Allred score. This is the first evidence that evaluation of ER(beta)cx along with PR may contribute to a better characterization of ER(alpha)-positive breast cancers.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Shigehira Saji, and Yoko Omoto, and Chikako Shimizu, and Margaret Warner, and Yukiko Hayashi, and Shin-ichiro Horiguchi, and Toru Watanabe, and Shin-ichi Hayashi, and Jan-Ake Gustafsson, and Masakazu Toi
September 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
Shigehira Saji, and Yoko Omoto, and Chikako Shimizu, and Margaret Warner, and Yukiko Hayashi, and Shin-ichiro Horiguchi, and Toru Watanabe, and Shin-ichi Hayashi, and Jan-Ake Gustafsson, and Masakazu Toi
January 2014, Breast cancer research and treatment,
Shigehira Saji, and Yoko Omoto, and Chikako Shimizu, and Margaret Warner, and Yukiko Hayashi, and Shin-ichiro Horiguchi, and Toru Watanabe, and Shin-ichi Hayashi, and Jan-Ake Gustafsson, and Masakazu Toi
September 2004, Clinical cancer research : an official journal of the American Association for Cancer Research,
Shigehira Saji, and Yoko Omoto, and Chikako Shimizu, and Margaret Warner, and Yukiko Hayashi, and Shin-ichiro Horiguchi, and Toru Watanabe, and Shin-ichi Hayashi, and Jan-Ake Gustafsson, and Masakazu Toi
January 2005, Anticancer research,
Shigehira Saji, and Yoko Omoto, and Chikako Shimizu, and Margaret Warner, and Yukiko Hayashi, and Shin-ichiro Horiguchi, and Toru Watanabe, and Shin-ichi Hayashi, and Jan-Ake Gustafsson, and Masakazu Toi
March 2008, The Journal of biological chemistry,
Shigehira Saji, and Yoko Omoto, and Chikako Shimizu, and Margaret Warner, and Yukiko Hayashi, and Shin-ichiro Horiguchi, and Toru Watanabe, and Shin-ichi Hayashi, and Jan-Ake Gustafsson, and Masakazu Toi
January 2004, Breast cancer research : BCR,
Shigehira Saji, and Yoko Omoto, and Chikako Shimizu, and Margaret Warner, and Yukiko Hayashi, and Shin-ichiro Horiguchi, and Toru Watanabe, and Shin-ichi Hayashi, and Jan-Ake Gustafsson, and Masakazu Toi
November 2001, European urology,
Shigehira Saji, and Yoko Omoto, and Chikako Shimizu, and Margaret Warner, and Yukiko Hayashi, and Shin-ichiro Horiguchi, and Toru Watanabe, and Shin-ichi Hayashi, and Jan-Ake Gustafsson, and Masakazu Toi
August 2006, Pathology international,
Shigehira Saji, and Yoko Omoto, and Chikako Shimizu, and Margaret Warner, and Yukiko Hayashi, and Shin-ichiro Horiguchi, and Toru Watanabe, and Shin-ichi Hayashi, and Jan-Ake Gustafsson, and Masakazu Toi
February 2020, Breast cancer research and treatment,
Shigehira Saji, and Yoko Omoto, and Chikako Shimizu, and Margaret Warner, and Yukiko Hayashi, and Shin-ichiro Horiguchi, and Toru Watanabe, and Shin-ichi Hayashi, and Jan-Ake Gustafsson, and Masakazu Toi
March 2007, BMC cancer,
Copied contents to your clipboard!